- Home
- INVE vs MIST Comparison
INVE vs MIST Comparison
Compare INVE & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | MIST |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 176.3M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVE | MIST |
|---|---|---|
| Price | $3.74 | $2.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.50 | ★ $8.50 |
| AVG Volume (30 Days) | 38.0K | ★ 9.9M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $0.63 |
| 52 Week High | $4.07 | $3.06 |
Technical Indicators
Market Signals| Indicator | INVE | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 42.62 |
| Support Level | $3.23 | $1.94 |
| Resistance Level | $3.70 | $2.14 |
| Average True Range (ATR) | 0.19 | 0.29 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 65.67 | 29.66 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).